GLASF
Price
$6.48
Change
-$0.03 (-0.46%)
Updated
Sep 26 closing price
Capitalization
514.41M
MEDIF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 26 closing price
Capitalization
21.12M
Interact to see
Advertisement

GLASF vs MEDIF

Header iconGLASF vs MEDIF Comparison
Open Charts GLASF vs MEDIFBanner chart's image
Glass House Brands
Price$6.48
Change-$0.03 (-0.46%)
Volume$88.56K
Capitalization514.41M
Medipharm Labs
Price$0.05
Change-$0.00 (-0.00%)
Volume$76.64K
Capitalization21.12M
GLASF vs MEDIF Comparison Chart in %
Loading...
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLASF vs. MEDIF commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLASF is a Hold and MEDIF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (GLASF: $6.48 vs. MEDIF: $0.05)
Brand notoriety: GLASF and MEDIF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GLASF: 42% vs. MEDIF: 69%
Market capitalization -- GLASF: $514.41M vs. MEDIF: $21.12M
GLASF [@Pharmaceuticals: Generic] is valued at $514.41M. MEDIF’s [@Pharmaceuticals: Generic] market capitalization is $21.12M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLASF’s FA Score shows that 0 FA rating(s) are green whileMEDIF’s FA Score has 0 green FA rating(s).

  • GLASF’s FA Score: 0 green, 5 red.
  • MEDIF’s FA Score: 0 green, 5 red.
According to our system of comparison, both GLASF and MEDIF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLASF’s TA Score shows that 4 TA indicator(s) are bullish while MEDIF’s TA Score has 3 bullish TA indicator(s).

  • GLASF’s TA Score: 4 bullish, 5 bearish.
  • MEDIF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GLASF is a better buy in the short-term than MEDIF.

Price Growth

GLASF (@Pharmaceuticals: Generic) experienced а -6.36% price change this week, while MEDIF (@Pharmaceuticals: Generic) price change was -2.81% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLASF($514M) has a higher market cap than MEDIF($21.1M). MEDIF YTD gains are higher at: 25.666 vs. GLASF (11.724). GLASF has higher annual earnings (EBITDA): 49M vs. MEDIF (-6.45M). GLASF has more cash in the bank: 40.7M vs. MEDIF (10.4M). MEDIF has less debt than GLASF: MEDIF (542K) vs GLASF (72.8M). GLASF has higher revenues than MEDIF: GLASF (222M) vs MEDIF (44.5M).
GLASFMEDIFGLASF / MEDIF
Capitalization514M21.1M2,436%
EBITDA49M-6.45M-760%
Gain YTD11.72425.66646%
P/E Ratio513.07N/A-
Revenue222M44.5M499%
Total Cash40.7M10.4M391%
Total Debt72.8M542K13,432%
FUNDAMENTALS RATINGS
GLASF vs MEDIF: Fundamental Ratings
GLASF
MEDIF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEDIF's Valuation (91) in the null industry is in the same range as GLASF (94). This means that MEDIF’s stock grew similarly to GLASF’s over the last 12 months.

MEDIF's Profit vs Risk Rating (100) in the null industry is in the same range as GLASF (100). This means that MEDIF’s stock grew similarly to GLASF’s over the last 12 months.

GLASF's SMR Rating (95) in the null industry is in the same range as MEDIF (96). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

GLASF's Price Growth Rating (61) in the null industry is in the same range as MEDIF (63). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

GLASF's P/E Growth Rating (100) in the null industry is in the same range as MEDIF (100). This means that GLASF’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLASFMEDIF
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 11 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GLASF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SFGCX14.710.13
+0.89%
NAA World Equity Income C
PSLAX16.370.13
+0.80%
Putnam Small Cap Value A
FTADX57.920.38
+0.66%
Fidelity Advisor International Discv M
MTCIX79.92N/A
N/A
MFS Technology I
MRNPX33.35-0.08
-0.24%
Morgan Stanley Inst International Opp IR

GLASF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLASF has been loosely correlated with TSNDF. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GLASF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLASF
1D Price
Change %
GLASF100%
-0.46%
TSNDF - GLASF
62%
Loosely correlated
-2.69%
GTBIF - GLASF
62%
Loosely correlated
-2.02%
TCNNF - GLASF
58%
Loosely correlated
+1.09%
VRNOF - GLASF
58%
Loosely correlated
-1.72%
CRLBF - GLASF
57%
Loosely correlated
-1.90%
More

MEDIF and

Correlation & Price change

A.I.dvisor tells us that MEDIF and SWGHF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDIF and SWGHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
-2.58%
SWGHF - MEDIF
29%
Poorly correlated
N/A
GLASF - MEDIF
25%
Poorly correlated
-0.46%
AAWH - MEDIF
23%
Poorly correlated
-3.12%
TCNNF - MEDIF
22%
Poorly correlated
+1.09%
CURLF - MEDIF
22%
Poorly correlated
-7.35%
More